Mariec.C-Pharma SRL

Mariec.C-Pharma reported total assets of 759,407 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Aug 2026).

Company number (CBE) 0507.640.788 · VAT BE0507640788
7180 Seneffe
active in Retail sale of pharmaceutical products (NACE 47730)
operating since 22 Dec 2014 (≈ 12 yrs)
Public Public page: latest year only. The score, history and details open with a free account. Create a free account
Idonis solidity score
EDCBA

The score of Mariec.C-Pharma shows with a free account.

See the score
Profile
SRL since 2014
Components
  • Summary? / 5
    • Balance sheet strength
    • Liquidity
    • Repayment capacity
    • Profitability
    • Trajectory
    • Compliance and register
  • Position in its sectorvs peers
  • Supplier creditat 30 d
  • Borrowing capacityborrowable
  • Valuationcentral

Visible once signed in: create your account, the 14-day Pro trial is free.

Detail

Key figures 2025

Net result−127,351 €
Equity288,410 €
Cash92,373 €
EBITDA−33,113 €
Total assets759,407 €
The line marks its sector median: 41.5% (1048 companies).

Change 2022 → 2025: Equity -18 % Total assets -8 %

Accounts of the company itself (not consolidated).

The full file covers 10 financial years; a free account shows 2. →

Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error

Mariec.C-Pharma's annual accounts

20252024202320222021
Net result−127,351 €
Equity288,410 €
Cash92,373 €
EBITDA−33,113 €
Total assets759,407 €

Filed annual accounts

  • Year ended 31 Dec 2025filed on 24 Aug 2026
  • Year ended 31 Dec 2024filed on 25 Aug 2025
  • Year ended 31 Dec 2023filed on 26 Aug 2024
  • Year ended 31 Dec 2022filed on 24 Aug 2023
  • Year ended 31 Dec 2021filed on 23 Aug 2022

Mariec.C-Pharma's financial analysis

Management and control of Mariec.C-Pharma

2 active director(s) in the register.

Mariec.C-Pharma's shareholders and holdings →

Mariec.C-Pharma's publications in the Belgian Gazette

Company number, VAT number and registered office

Company number (CBE)
0507.640.788
VAT number
BE0507640788
Peppol
Registered · 0208:0507640788 · as of 10 Nov 2026
Legal form
SRL
Incorporated
22 Dec 2014
Registered office
7180 Seneffe
Latest accounts
2025 · filed on 24 Aug 2026
Activity
Retail sale of pharmaceutical products (NACE 47730)

Mariec.C-Pharma (SRL) has been based in Seneffe since 2014, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 127,351 € and equity of 288,410 €; its revenue is not published. Its solvency stands at 38.0%, below the median of its sector (41.5%).

Guide: Reading Belgian SME accounts: the five figures that count →

Companies similar to Mariec.C-Pharma

Companies in the same business, of comparable size and area, outside its group.

Frequently asked questions about Mariec.C-Pharma

What is the revenue of Mariec.C-Pharma?

Mariec.C-Pharma files its accounts in a format where revenue is optional: it is not published for 2025.

What is the VAT number of Mariec.C-Pharma?

In Belgium, the VAT number is the company number prefixed with BE: BE0507640788 for Mariec.C-Pharma, if the company is VAT-registered. Its company number (CBE) is 0507.640.788.

Where is the registered office of Mariec.C-Pharma?

According to the CBE register, the registered office of Mariec.C-Pharma is in 7180 Seneffe.

What is the equity of Mariec.C-Pharma?

At the close of the 2025 financial year, the equity of Mariec.C-Pharma amounts to 288,410 €, a solvency of 38.0% of total assets.

Who manages Mariec.C-Pharma?

The register lists 2 active mandates at Mariec.C-Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.

Idonis

The full file of Mariec.C-Pharma

Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.

Open the full file →
Free account in 30 seconds, by email. No bank card.
Sources : Annual accounts — NBB ↗ Register — CBE ↗ Deeds — Belgian Gazette ↗ · Updated on 27 Aug 2026

No credit card, no commitment.

What each plan unlocks →